Investing.com - Financial Markets Worldwide

Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ
Symbol
Exchange
Currency
9.51
-0.06(-0.63%)
-Closed.
Currency in USD
After Hours
9.65
+0.14(+1.47%)
- Real-time Data
  • Volume:
    2,532,861
  • Day's Range:
    9.36 - 9.78
  • 52 wk Range:
    4.07 - 13.41

AUPH Comments

What is your sentiment on Aurinia Pharma?
or
Market is currently closed. Voting is open during market hours.

All Comments

(80)
  • shorts running out of powder?
    0
    • Shorts have strong conviction. Could gamma squeeze this week? I would like to see it. OOO AAAH
      0
      • shorts. lol!!!!
        0
        • BOOM!
          0
          • triple witching, $20 options close to being in the money, high short interest. Something to watch!
            0
            • so should I continue holding?
              0
            • Arnold Anderson absolutely!
              0
          • Friday fun day!
            0
            • margin calls ******
              0
              • T/A will go away and F/A will take over on this one or a BO. Either way she going up.
                0
                • popcorn for breakfast! YES!!!
                  0
                  • Calm before the storm.
                    0
                    • Shorts are really rolling the dice here. lol
                      0
                      • shorts might be in trouble here. Push $20 and it will run.
                        0
                        • Buyout coming, waiting for 30+
                          0
                          • 30+? What is your reasoning for that share price?
                            0
                        • Looking strong!
                          0
                          • gamma gamma gamma
                            0
                            • BOOM!
                              0
                              • Squeeze!!!
                                0
                                • Nice movement. Shorts should exit. lol!
                                  0
                                  • Acquisition happening! ⚡⚡🚀🚀
                                    0
                                    • nice surprise in revenues. Could double/triple within 24 months imo.
                                      0
                                      • beautiful!
                                        0
                                        • AUPH reported positive data as competitors 'stumble,' says H.C. Wainwright analyst Ed Arce noted that (AUPH) announced that a "supportive interim analysis" of its AURORA 2 study will be presented at EULAR, held June 2-5. The new data will represent the longest-available outcomes data for LUPKYNIS to date for the treatment of lupus nephritis, or LN, said Arce. Meanwhile, competitor Boehringer Ingelheim announced in a poster presentation at EULAR that its anti-CD40 mAb, BI655064, failed to meet its primary endpoint of complete renal response and Eli Lilly (LLY) disclosed in a recent quarterly filing that TULIP-LN1, its Phase 2 study of anifrolumab, also failed to meet its primary endpoint, according to Arce. The analyst, who maintains his 100% odds of approval view for LUPKYNIS in the U.S., keeps a Buy rating and $35 price target on Aurinia shares. AUPH LLY
                                          0
                                          • oh she is showing some life! Go Aurinia
                                            0
                                            • Turning point is 12.50-60 , buy heavy.
                                              0
                                              • What time earnings news tomorrow?
                                                0